ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Sumitomo Dainippon Pharma Co., Ltd.

Business Summary

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue459,267M4,141.47M
Gross Profit337,856M3,046.63M
Operating income57,207M515.86M
Income before tax65,046M586.55M
Net income48,627M438.49M
EBITDA71,183M641.89M
Diluted EPS122.391.10
Dividends Per Share280.25
Total Assets834,717M7,541.37M
Total liabilities336,555M3,040.65M
Total equity498,138M4,500.50M
Operating cash flow48,711M439.25M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 371,370M 403,206M 408,357M 466,838M 459,267M
Gross Profit 265,014M 293,016M 307,911M 347,955M 337,856M
Operating income 23,275M 36,929M 60,974M 79,643M 57,207M
Income before tax 33,755M 39,560M 42,781M 84,866M 65,046M
Net income 15,447M 24,697M 31,316M 53,448M 48,627M
EBITDA 42,501M 57,194M 73,687M 92,530M 71,183M
Diluted EPS 38.87 62.16 78.82 134.53 122.39
Dividends Per Share 18 18 20 28 28
Total Assets 711,583M 707,715M 779,072M 809,684M 834,717M
Total liabilities 260,562M 261,243M 366,804M 356,961M 336,555M
Total equity 451,021M 446,472M 412,268M 452,723M 498,138M
Operating cash flow 32,523M 52,486M 19,143M 93,420M 48,711M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 3,380.50M 3,357.69M 3,771.04M 4,212.10M 4,141.47M
Gross Profit 2,412.36M 2,440.08M 2,843.45M 3,139.46M 3,046.63M
Operating income 211.86M 307.52M 563.07M 718.58M 515.86M
Income before tax 307.26M 329.43M 395.06M 765.71M 586.55M
Net income 140.61M 205.66M 289.19M 482.24M 438.49M
EBITDA 386.87M 476.28M 680.47M 834.86M 641.89M
Diluted EPS 0.35 0.51 0.72 1.21 1.10
Dividends Per Share 0.16 0.14 0.18 0.25 0.25
Total Assets 5,933.56M 6,296.67M 6,991.58M 7,613.38M 7,541.37M
Total liabilities 2,172.70M 2,324.32M 3,291.78M 3,356.47M 3,040.65M
Total equity 3,760.85M 3,972.34M 3,699.79M 4,256.91M 4,500.50M
Operating cash flow 296.04M 437.07M 176.77M 842.89M 439.25M

Valuation Measures

Mar 2019
PER22.36
ROA5.91%
ROE10.22%
Operating margin12.45%
Profit margin10.58%

Key executives

  • President & Representative Director: Hiroshi Nomura
  • GM-Production, Head-Research & Technology: Yoshiharu Ikeda
  • Executive Officer: Antony Loebel
  • Executive Officer: Shigeyuki Nishinaka
  • Director & Managing Executive Officer: Toru Kimura

Shareholders

  • Sumitomo Chemical Co., Ltd. (51.6%)
  • Inabata & Co., Ltd. (4.8%)
  • Nomura Asset Management Co., Ltd. (3.5%)
  • Nippon Life Insurance Co. (1.9%)
  • Sumitomo Mitsui Banking Pension Fund (1.7%)
  • Nikko Asset Management Co., Ltd. (1.7%)
  • Daiwa Asset Management Co. Ltd. (1.6%)
  • Sumitomo Life Insurance Co. (1.4%)
  • MS&AD Insurance Group Holdings, Inc. (1.4%)
  • The Vanguard Group, Inc. (1.1%)

Contact Details

Related Companies

  • Sumitovant Biopharma Ltd. (London)
  • Sumitovant Biopharma Ltd.
  • Sumitomo Dainippon Pharma Pension Fund
  • Urovant Sciences Ltd.
  • Myovant Sciences Ltd.
  • Dainippon Sumitomo Pharma America Holdings, Inc.
  • Sunovion Pharmaceuticals Asia Pacific Pte Ltd.
  • Sumitomo Pharmaceuticals (Suzhou) Co. Ltd.
  • Sunovion Pharmaceuticals Europe Ltd.
  • Sumitomo Dainippon Pharma Trust
  • Sumitomo Dainippon Pharma Employee Stock Ownership Plan
  • Kyowa Hakko Pharmaceuticals (Suzhou) Co. Ltd.
  • Tanabe Seiyaku Co., Ltd. /Pet Medicine Operations/
  • Tolero Pharmaceuticals, Inc.
  • Boston Biomedical, Inc.
  • Sunovion Pharmaceuticals, Inc.

Competitors

  • VistaGen Therapeutics, Inc.
  • Intra-Cellular Therapies, Inc.
  • Vanda Pharmaceuticals Inc.
  • Alkermes Plc
  • Axovant Gene Therapies Ltd.
  • Xenon Pharmaceuticals Inc.
  • Voyager Therapeutics, Inc.
  • Innoviva, Inc.
  • Neos Therapeutics, Inc.
  • ERYTech Pharma SA
  • Karuna Therapeutics, Inc.
  • Marinus Pharmaceuticals Inc
  • Stemline Therapeutics, Inc.
  • Adamas Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Verona Pharma plc
  • Circassia Pharmaceuticals Plc
  • Supernus Pharmaceuticals, Inc.
  • Acorda Therapeutics, Inc.
  • BioLineRX Ltd.
  • Aravive, Inc.
  • OptiNose, Inc.
  • Qurient Co., Ltd.
  • SCYNEXIS, Inc.
Last Updated on 27 Mar, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends April 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media